J&J/McNeil Done With Post-Recall Personnel Changes - CEO Weldon
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson has finished culling its ranks of employees responsible for quality control lapses that led to extensive OTC recalls, according to CEO William Weldon.
You may also be interested in...
Novartis Opts For OTC Recall, With J&J/McNeil Lessons Still Fresh
After shuttering its Lincoln, Neb., OTC facility, the firm recalls some lots of Bufferin, Excedrin, Gas-X and NoDoz. FDA found a “pattern of problems” when inspecting the plant in 2011, and Novartis’ actions suggest it seeks to avoid the same scrutiny that Johnson & Johnson’s OTC recalls elicited.
Novartis Opts For OTC Recall, With J&J/McNeil Lessons Still Fresh
After shuttering its Lincoln, Neb., OTC facility, the firm recalls some lots of Bufferin, Excedrin, Gas-X and NoDoz. FDA found a “pattern of problems” when inspecting the plant in 2011, and Novartis’ actions suggest it seeks to avoid the same scrutiny that Johnson & Johnson’s OTC recalls elicited.
In Brief
FDA releases drug patch guidance